Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 8/20 | 0.39 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | NMT1 | P30419 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069073 | 1.00 | AKR1C3 (0.42) | AKR1C3APEX1GPR35NMT1KDM4E | |
| SCHEMBL19967035 | 0.89 | AKR1C3 (0.42) | AKR1C3APEX1GPR35KDM4EALDH1A1 | |
| SCHEMBL127221 | 0.86 | AKR1C3 (0.44) | AKR1C3APEX1ALDH1A1LMNA | |
| SCHEMBL127220 | 0.86 | AKR1C3 (0.44) | AKR1C3APEX1ALDH1A1LMNA | |
| SCHEMBL15199397 | 0.83 | TTR (0.48) | AKR1C3APEX1GPR35 | |
| SCHEMBL16224162 | 0.83 | TTR (0.48) | AKR1C3APEX1GPR35 | |
| SCHEMBL21470298 | 0.80 | EIF4A3 (0.42) | AKR1C3APEX1KDM4E | |
| SCHEMBL122734 | 0.80 | AKR1C3 (0.45) | AKR1C3APEX1LMNATDP1 | |
| SCHEMBL122735 | 0.80 | AKR1C3 (0.45) | AKR1C3APEX1LMNATDP1 | |
| SCHEMBL7820417 | 0.78 | AKR1C3 (0.53) | AKR1C3APEX1ALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889722-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2014-11-18 | — | — | US | disclosed |
| EP-2184279-B1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF | SHIONOGI & CO (JP) | 2014-11-12 | — | — | EP | disclosed |
| US-8530668-B2 | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor | SHIONOGI & CO., LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-20130217885-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | SHIONOGI & CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20100267783-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | EDDINGPHARM (HONG KONG) COMPANY LIMITED (CN) | 2010-10-21 | — | — | US | disclosed |
| EP-2184279-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY AND INTERMEDIATE THEREOF | Shionogi&Co., Ltd. (JP) | 2010-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267783-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | MPL, TEK, THPO | AKR1C3 1103/4885APEX1 4762/4885GPR35 138/4885 |
| US-20130217885-A1 | PHARMACEUTICAL COMPOSITION CONTAINING OPTICALLY ACTIVE COMPOUND HAVING THROMBOPOIETIN RECEPTOR AGONIST ACTIVITY, AND INTERMEDIATE THEREFOR | MPL, TEK, THPO | AKR1C3 1146/4885APEX1 4755/4885GPR35 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.